Acerca de

Axil Capital was spun out of Mizuho Securities in 2017, with early investors that include Mizuho, the Japanese government, a global pharmaceutical company, and a small group of corporate visionaries from inside and outside of Japan. Our goal is to create synergies between the biotech ecosystem in Japan and the rest of the world, to build companies with long term value and generate sustainable returns for our investors.

We specialize in identifying, evaluating, executing and nurturing our investments that span the full spectrum of the life science industry. We diversify our portfolio by investing in early-stage venture capital as well as late-stage crossover round deals. We focus on transformational technologies and services that can have a long-term impact on the medical community and society at large while generating tangible returns to our investors.